Statement of Principles concerning chronic obstructive pulmonary disease (Balance of Probabilities) (No. 18 of 2023)

This instrument, the Repatriation Medical Authority Statement of Principles (No. 18 of 2023) concerning chronic obstructive pulmonary disease (COPD), sets out the medical criteria that will be applied, pursuant to the Veterans' Entitlements Act 1986 (VEA), when assessing whether COPD or death from COPD is connected with a person’s relevant service. It is made under subsection 196B(3) of the VEA (s 3) and takes effect on 27 March 2023 (s 2). The instrument expressly repeals the prior Statement of Principles for COPD (No. 38 of 2014) (s 4). It applies to claims to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 (MRCA) apply (s 5).

Mechanically, the Statement performs these functions:

• It defines the kind of injury or disease covered, giving a working clinical definition of chronic obstructive pulmonary disease, listing included entities (chronic bronchitis, emphysema, persistent airflow limitation) and a short list of explicit exclusions (for example, asbestosis and asthma) (s 7(2)(a)-(c)). The Schedule supplies further definitional detail including the spirometric threshold for persistent airflow limitation (post‑bronchodilator FEV1/FVC < 0.7) and definitions for pack‑year and joint‑year calculations (Schedule 1).
• It records the Repatriation Medical Authority’s view, on the available medical and scientific evidence, that it is more probable than not that COPD and death from COPD can be related to relevant service (s 8). This articulates the evidentiary standard the RMA relied upon when setting the Statement.
• It enumerates specific exposure, disease and personal history factors which must exist before causation on the balance of probabilities can be accepted. These factors are thresholded and time‑bounded , for example, minimum pack‑year smoking exposure, minimum cumulative hours of exposure to second‑hand smoke, thresholds for inhalational exposures in enclosed or open environments, concentrations for particular substances, and time windows for cessation or prior disease (s 9).
• It clarifies the required relationship to service: any listed factor must be related to the person’s relevant service (s 10(1)). It adds that the factors in subsections 9(14) to 9(29) apply only to material contribution to, or aggravation of, COPD where the COPD was suffered or contracted before or during (but did not arise out of) the person’s relevant service (s 10(2)).
• It provides an interaction rule for overlapping Statements: where a factor refers to an injury or disease covered by another Statement, the other Statement applies in accordance with its terms as in force from time to time (s 11).

The instrument is prescriptive about measurable thresholds and temporal limits. Examples include: at least 5 pack‑years of tobacco smoking before clinical onset, or 20,000 cumulative hours of second‑hand smoke exposure before clinical onset (s 9(1)-(2)); minimum cumulative hours for inhaling polluting fuel smoke in an enclosed space (10,000 hours) with a 20‑year cessation window (s 9(4)); substance‑specific concentration thresholds recorded in the Schedule for cadmium fumes (>0.00001 mg/m3) and sulphur dioxide (>0.1 ppm) (Schedule 1). The Schedule also defines key terms used throughout the Statement, such as “polluting fuels”, “lower respiratory tract”, and “terminal event”.

This Statement does not itself set entitlement outcomes or benefits; it supplies the medical causation framework that will be applied in claims under the VEA or MRCA as specified. The instrument contains no penalty provisions or enforcement mechanisms within its text; it is a determinative medical standard to be used in administrative decision‑making under the Acts identified (s 5, s 3, s 8).

The Statement organises a small number of core legal and clinical concepts that will govern causation assessments for COPD and death caused by COPD. Those concepts are:

1. Definition of the disease for the instrument’s purposes (s 7(2)). The instrument sets a clinical definition: COPD is a chronic progressive inflammatory pathology with varying involvement of airways, lung parenchyma and vasculature. It expressly includes chronic bronchitis, emphysema and persistent airflow limitation; it expressly excludes a discrete list of conditions such as asbestosis and surgical or localised emphysema (s 7(2)(a)-(c)). The instrument states that, although COPD corresponds to ICD‑10‑AM codes J41-J44, the operative definition is the statutory one given in subsection 7(2) (s 7(3)-(4)).

2. Probabilistic basis for causation (s 8). The Repatriation Medical Authority states its view, based on the medical‑scientific evidence before it, that on the balance of probabilities COPD and death from COPD can be related to relevant service. This is an explicit articulation of the standard of proof the Authority used in drafting the Statement.

3. Discrete causation factors with numeric thresholds and timing windows (s 9). The Statement lists alternative factors, any one of which, if related to relevant service, is sufficient to establish causation on the balance of probabilities. The factors are numerically thresholded (for example, 5 pack‑years, 20 joint‑years), time‑bounded in relation to cessation (for example, onset occurring within 20 years of smoking cessation), and environmental exposures are expressed as cumulative hours or concentration thresholds (for example, 20,000 cumulative hours of exposure to second‑hand smoke; respirable dust >5 mg/m3 at cumulative exposures of 20,000 hours). The Statement distinguishes between factors that establish causation for clinical onset (s 9(1)-(13)) and factors that establish causation for clinical worsening or material contribution/aggravation (s 9(14)-(29)), with separate thresholds for each.

4. Relationship to service (s 10). A listed factor must be related to the person’s relevant service. The Statement further circumscribes the application of factors directed to material contribution or aggravation so that they only apply where COPD was suffered or contracted before or during (but did not arise out of) service (s 10(2)).

5. Interaction with other Statements of Principles (s 11). Where a factor references an injury or disease already subject to another Statement, that other Statement applies according to its own terms. This creates a rule for resolving overlap between Statements.

The instrument identifies the population it governs and the actors who will need to engage with it. Primary affected groups include:

• Claimants: veterans and members of the Forces who lodge claims to which section 120B of the VEA or section 339 of the MRCA apply. The Statement is framed to be applied to a person’s claim for COPD or death from COPD when those provisions are engaged (s 5, s 8). Claimants who have COPD, or who died from COPD, and who assert a connection to relevant service are directly affected because the Statement establishes the medical criteria that will be applied in assessing causation.

• Clinicians and medical assessors: clinicians preparing medical reports or performing spirometry must provide the type of documentation contemplated by the Schedule and by the causation factors. For example, proof of persistent airflow limitation requires post‑bronchodilator spirometry with FEV1/FVC < 0.7 (Schedule 1). When an exposure factor requires demonstration of acute lower respiratory tract injury needing medical attention within 48 hours and persistence of symptoms for at least one week, clinicians will be expected to record these events with appropriate dates and treatment details (s 9(5), s 9(18)).

• Decision‑makers under the VEA and MRCA: administrative officers adjudicating claims will use the Statement as the medical causation standard. The text explicitly targets claims governed by particular sections of the VEA and the MRCA (s 5), so agencies and staff responsible for deciding those claims will apply the thresholds and temporal limits stated.

• Evidence preparers and employers: people or organisations called on to provide occupational histories, rosters, shift patterns, workplace exposure assessments, or environmental monitoring to substantiate cumulative exposure hours or concentration levels. The factors require cumulative hours and concentrations that cannot usually be demonstrated without contemporaneous records or retrospective reconstruction.

• Relatives or representatives in death cases: where a person died from a terminal event contributed to by COPD (s 7(5)), dependants or executors who make claims tied to the deceased’s service will need to document the terminal event and its connection to COPD.

The Statement does not itself create new liabilities for private parties, nor does it create criminal or civil penalties; rather it modifies the administrative evidentiary landscape for entitlement claims under the VEA and MRCA (s 5, s 3). The instrument’s thresholds will influence the behaviour of claimants and practitioners because meeting or failing to meet its numeric thresholds will materially affect the probability of an administrative causation finding.

The instrument establishes a set of legal criteria rather than prescriptive duties or affirmative statutory rights. However, it creates de facto obligations for certain actors and clarifies the rights of claimants insofar as they relate to the establishment of causation.

Rights and legal effects

• Right to have causation assessed against the Statement: A claimant who brings a claim covered by section 120B of the VEA or section 339 of the MRCA is entitled to have medical causation for COPD or death from COPD assessed with reference to this Statement (s 5). The Statement sets out factors which, if present and related to relevant service, permit a finding on the balance of probabilities that COPD is connected with service (s 9, s 8).

• Disease definition governs: The statutory definition of COPD in s 7(2) controls the scope of what may be claimed under this Statement. Even though corresponding ICD‑10‑AM codes are noted (s 7(3)-(4)), the operative definition is the instrument’s; therefore claimants and clinicians must map clinical diagnoses onto the statutory wording.

Duties and evidentiary expectations

• Duty to demonstrate factors related to service: Subsection 10(1) requires that any factor listed in s 9 must be related to the person’s relevant service. Practically, this creates an obligation on the claimant to provide evidence linking the qualifying factor to service, for example by showing that exposure hours occurred while performing relevant service duties (s 10(1), s 9).

• Duty to provide timing and quantity evidence: Many factors are expressed as quantitative thresholds and time windows. For example, one of the alternative bases for causation is smoking at least 5 pack‑years prior to clinical onset (s 9(1)). The Schedule explains pack‑year calculations and provides examples and gram equivalents (Schedule 1, Notes 1-2). Similarly, exposure thresholds are stated in cumulative hours (for second‑hand smoke, polluting fuel smoke, inorganic or organic dust) or concentrations (cadmium fumes, sulphur dioxide gas) (s 9; Schedule 1). Claimants and their advisors must assemble records, workplace exposure assessments, medical histories, spirometry results, and other evidence that will permit an adjudicator to conclude the threshold and service relation are met.

• Duty to account for cessation windows: Several factors impose cessation windows , e.g. clinical onset occurring within 20 years of smoking cessation (s 9(1)(b)). Where cessation has occurred, claimants must be able to show relevant dates. This imposes a temporal evidentiary duty on claimants.

The Statement of Principles instrument does not itself prescribe penalties or enforcement mechanisms. It is a medical standard, determined under subsection 196B(3) of the VEA (s 3), intended for use in the adjudication of claims under specific statutory provisions (s 5). No section of the instrument creates offences, civil liabilities, monetary penalties, or enforcement procedures.

How the Statement is enforced in practice

• Administrative application: Enforcement of the Statement’s effect occurs administratively through application in decisions under the VEA and MRCA. The instrument is a determinative tool for causation; decision‑makers under the VEA and MRCA will apply it when assessing whether COPD or death from COPD is connected with relevant service. The Statement therefore functions as a substantive input to entitlement decisions made under other Acts rather than as a self‑executing regulatory instrument.

• Evidentiary consequences: The primary sanctioning effect is evidentiary. If a claimant cannot demonstrate that any of the factors in s 9 existed and were related to relevant service, then the administrative outcome will be that causation on the balance of probabilities is not established. Conversely, satisfying a listed factor and the relationship to service will make a causation finding more likely.

Risks and implementation issues relevant to enforcement

• Administrative discretion and fact finding: The instrument establishes thresholds and definitions but necessarily leaves fact finding to decision‑makers. For example, determination of whether exposure was for the cumulative number of hours required (20,000 hours, 10,000 hours, etc.) is a factual exercise that will depend on records, witness statements, or expert opinion. The instrument itself does not specify methodologies for reconstructing hours or converting workplace exposure data into the cumulative hours stated.

• Interaction with other Statements: Section 11 requires that where a factor refers to an injury or disease covered by another Statement, that other Statement applies. This creates a regime where enforcement of causation may involve cross‑reference and interpretation across Statements, potentially increasing administrative complexity and dispute about which Statement governs.

• No express appeal or review mechanism in the instrument: The Statement does not specify appeal or review routes. Those procedural mechanisms exist in the VEA and MRCA regimes but are not re‑stated here. Any contested application of the Statement will therefore be addressed through the statutory review and appeal pathways in the governing Acts, not through provisions within this Statement.

The Statement is expressly designed to operate within the statutory frameworks of the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. The instrument identifies the specific statutory touchpoints and contains rules for interaction with other Statements of Principles.

Statutory application

• Targeted claim provisions: The Statement applies to claims to which section 120B of the VEA or section 339 of the MRCA apply (s 5). It is therefore an instrument meant to be read and applied in the adjudication of those statutory avenues for veteran or service‑related compensation or entitlements. The instrument does not purport to amend or replace provisions of the VEA or MRCA; rather it furnishes the medical causation standard for adjudicators operating under those Acts.

• Authority under the VEA: The Statement is made under subsection 196B(3) of the VEA (s 3). That is the statutory power by which the Repatriation Medical Authority determines Statements of Principles; the Statement’s legal provenance is therefore embedded in the VEA.

Interaction with other Statements

• Cross‑Statement application rule: Section 11 provides that where a factor in this Statement refers to an injury or disease that is the subject of another Statement of Principles under subsection 196B(3) of the VEA, then the factors in that other Statement apply according to its terms as in force from time to time. This means that where, for example, a factor such as “pulmonary tuberculosis” is implicated and there is a separate Statement addressing pulmonary tuberculosis, an adjudicator must apply that other Statement’s factors. Section 9 itself lists pulmonary tuberculosis as a factor (s 9(10), s 9(24)) and the Schedule defines “pulmonary tuberculosis” (Schedule 1). The cross‑reference rule ensures consistency across the RMA’s Statements but introduces the need to identify the governing Statement for particular concurrent diagnoses.

Relationship to diagnostic coding

• ICD‑10‑AM codes acknowledged but subordinate: The instrument notes that COPD attracts ICD‑10‑AM codes J41-J44, and defines what is meant by a reference to an ICD‑10‑AM code (s 7(3)-(4)). However, it also stipulates that for the purposes of the Statement the meaning of COPD is that given in subsection 7(2). Thus, ICD codes are informational rather than determinative. Decision‑makers must use the statutory definition rather than rely solely on an ICD coding entry.

This instrument contains a concise amendment and commencement history within its own text. Key historical points are:

• Repeal of prior Statement: The Statement expressly repeals the Statement of Principles concerning chronic obstructive pulmonary disease No. 38 of 2014 (Federal Register of Legislation No. F2014L00475), which had been made under subsections 196B(3) and (8) of the VEA (s 4). The repeal means the 2014 instrument is no longer the operative Statement for COPD; the 2023 Statement replaces it.

• Instrument identification and dates: The instrument is titled as the Statement of Principles concerning chronic obstructive pulmonary disease (Balance of Probabilities) (No. 18 of 2023) (s 1). It is dated 27 February 2023 (the instrument is signed on that date), and it commences on 27 March 2023 (s 2). Those dates identify when the Statement was finalised and when it came into force.

• Authority under the VEA: The instrument is made under subsection 196B(3) of the VEA (s 3). Although the Statement itself does not record any further amendments subsequent to commencement, the RMA’s power to determine Statements under subsection 196B(3) implies that further Statements, amendments, or repeals can be made by the RMA in the future under the same statutory power. Such future action would be recorded in subsequent Statements or instruments.

What is not included in the instrument’s amendment record

• The instrument does not contain a history of previous revisions other than the explicit repeal of the 2014 Statement. It does not provide an explanatory memorandum or second reading speech within the text, nor does it include an annexed history of consultation, evidence reviews, or prior drafts. The text speaks of “sound medical‑scientific evidence” as the basis for determination (s 8), but the instrument itself does not append or summarise that evidence.

• No transitional provisions are set out beyond the repeal. The instrument does not explicitly address whether claims lodged before commencement will or will not be assessed under the prior 2014 Statement. Practitioners therefore need to examine the governing Acts and agency practice to determine transitional application in individual cases.

Practical consequence for practitioners

• Replacement of prior standard: From 27 March 2023, the 2023 Statement and its specified thresholds govern causation assessments for COPD and death from COPD in claims covered by the cited statutory provisions (s 5). The repeal of the 2014 Statement means that older causation thresholds and definitions no longer apply, and practitioners must use the new definitions, numeric thresholds, cessation windows and Schedule definitions in preparing or defending claims.

The text provided contains no case law, judicial decisions, or references to litigation that interpret or challenge this specific Statement of Principles. The instrument itself is a non‑judicial administrative instrument determined by the Repatriation Medical Authority under subsection 196B(3) of the VEA (s 3). It does not record any litigation history, nor does it cite legal challenges.

Implications and likely sources of dispute

• Areas likely to generate litigation: Although no litigation history is recorded in the instrument, the structure and content of the Statement reveal a number of issues that could be contested in administrative review or litigation under the VEA or MRCA framework. Potential contentious areas include the factual application of quantitative thresholds (pack‑years, joint‑years, cumulative exposure hours), the interpretation of temporal windows for cessation, the appropriate mapping of clinical diagnoses to the statutory definition of COPD (s 7(2)), and the question of whether an exposure or disease factor was “related to” the person’s relevant service (s 10(1)). These are factual or legal issues that typically give rise to disputes requiring review.

• Cross‑Statement complexity: Section 11’s interaction rule, which requires that factors referring to injuries or diseases covered by other Statements be determined under those Statements, may prompt disagreements as to which Statement governs overlapping diagnostic or exposure circumstances. Such jurisdictional and interpretive questions often surface in appeals or reviews.

Absence of cases in the instrument

• No named authorities or precedents: The Statement does not cite or rely on judicial decisions or administrative precedents. It expressly sets out the RMA’s view based on the sound medical‑scientific evidence available (s 8). Any judicial interpretation of the Statement would therefore depend on post‑commencement case law, which is not recorded here.

Practical note for practitioners

• Where disputes occur they will be resolved under the procedural and review mechanisms provided in the VEA and MRCA, not by reference to the Statement alone. Practitioners should prepare to support factual claims with contemporaneous records, occupational exposure data, expert medical reports, and spirometry or laboratory evidence matched to the Schedule definitions. Where the Statement’s thresholds are applied in an adverse decision, review avenues under the governing Acts should be pursued.

This Statement contains a number of technical features, definitional traps, and practical evidence challenges that can substantially affect claim outcomes. The following items are practical “gotchas” for practitioners, clinicians, and claimants, grounded in the instrument’s text.

1. Disease exclusions versus risk factors: The Statement excludes asthma from the definition of COPD (s 7(2)(c)(ii)), yet asthma is also listed as a factor which, if present before clinical onset, may establish causation (s 9(12) and s 9(26) for worsening). This can appear contradictory. The practical point: asthma as a separate diagnosis is excluded from the COPD definition, but a prior history of asthma is recognised by the RMA as a predisposing factor for COPD when it existed before onset or worsening. Practitioners must therefore document both the asthma diagnosis (timing relative to COPD onset) and map it to the factor provisions rather than assuming asthma is automatically excluded from evidentiary consideration.

2. “Clinical onset” and “clinical worsening” are not defined: The instrument uses these critical temporal markers throughout s 9 but does not define them in the Schedule. This omission leaves contested room for interpretation as to when a claimant’s COPD first clinically manifested and when a worsening occurred. Adjudicators will need to infer onset/worsening dates from records and expert opinion, which opens a fact‑finding battleground.

3. Measurement of cumulative hours: Multiple factors are expressed in cumulative hours (for example, 20,000 hours for second‑hand smoke, 10,000 hours for polluting fuel smoke in an enclosed space, 20,000 hours for vapour/gas/fumes in enclosed spaces, 40,000 hours for open environments) (s 9(2), s 9(4), s 9(6)-(7)). The Statement does not prescribe how cumulative hours should be calculated from shift records, employment durations, or intermittent exposures. Practitioners must prepare to reconstruct hours and justify methodology; absence of clear contemporaneous records will complicate proof.

4. Concentration thresholds that are unusually precise: The Schedule specifies concentration thresholds such as cadmium fumes >0.00001 mg/m3 and sulphur dioxide gas >0.1 ppm (Schedule 1, specified list of substances). Demonstrating that workplace air met these thresholds requires industrial hygiene monitoring data. Anecdotal evidence or general workplace descriptions will not suffice; claimants will need documented air monitoring or expert opinion to meet these numeric cutoffs.

Compliance in this context means assembling the factual and medical evidence that will satisfy the Statement’s thresholds and demonstrating the relationship of those factors to the person’s relevant service. The following is a practical, source‑grounded compliance checklist for claimants, clinicians, advisors and decision‑makers based on provisions in the Statement and the Schedule.

1. Confirm applicability of the instrument

• Verify that the claim is one to which section 120B of the VEA or section 339 of the MRCA applies (s 5). If the claim falls outside those sections, the Statement will not govern the causation assessment.

2. Establish the clinical diagnosis in statutory terms

• Map the clinical diagnosis to subsection 7(2). Ensure the person’s condition falls within the instrument’s definition of COPD: chronic progressive inflammatory pathology with involvement of airways, parenchyma or vasculature; chronic bronchitis, emphysema and persistent airflow limitation are included (s 7(2)(a)-(b)).
• Provide spirometry: obtain post‑bronchodilator FEV1 and FVC measurements and calculate the FEV1/FVC ratio. For persistent airflow limitation the Schedule requires a post‑bronchodilator FEV1/FVC < 0.7 (Schedule 1). Ensure tests are recent, performed to standard, and include raw values and interpretation.

3. Identify which causation factor(s) in s 9 you will rely on

• Review s 9(1)-(13) for factors that establish causation for clinical onset, and s 9(14)-(29) for factors that establish material contribution to or aggravation where COPD was suffered or contracted before or during service (s 10(2)).
• For each selected factor, note the exact quantitative threshold and any temporal window for cessation or prior disease.

4. Assemble exposure and history evidence aligned to thresholds

• Smoking history: calculate pack‑years precisely per the Schedule. Use Note 2 for calculation method: divide cigarettes per day by 20 and multiply by years smoked (Schedule 1, Notes 1-2). Where tobacco products other than cigarettes were used, use the gram equivalence set out in Note 1. Document dates of commencement and cessation to assess cessation windows (s 9(1)(b), s 9(14)(b)).
• Cannabis use: calculate joint‑years per Schedule definition (1 joint per day for 1 year = 1 joint‑year) and document timing relative to onset/worsening (s 9(3), s 9(16); Schedule 1).